Results from the Phase III TOLEDO study suggests that treatment of Parkinson’s with apomorphine increases periods of good motor control and reduces periods when Parkinson’s disease medications are ineffective.
Browsing: Parkinson’s disease
Dopamine agonists and prodrugs taken to treat Parkinson’s disease may cause impulse control disorders in over half the patients they are prescribed to.
According to a large study, individuals with Type 2 diabetes may have an increased risk of being diagnosed with Parkinson’s disease later in life.
This week’s industry news round-up reveals the latest updates around spinal muscular atrophy, Parkinson’s disease and acute stroke.
A recently published study has indicated that all degrees of concussion may increase the risk of developing Parkinson’s disease.
Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson’s disease
This research article from Neurodegenerative Disease Management investigates how age and disease duration affects Parkinson’s treatment outcome with levodopa-carbidopa intestinal gel.
In this week’s round-up, we cover the latest industry news from depression and Parkinson’s disease. Find out more about our selection of the highlights this week.
Researchers have uncovered the role of calcium and how it interacts with alpha-synuclein in the development of Parkinson’s disease.
Pharmaceutical policy announcements, promising drug trial data and more: check out our round-up of the biggest news from the neuroscience and neurology industry this week
A new study from TauRx reports success in reversing symptoms of Parkinson’s disease in mouse models treated with LTMX.